AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 232 min read$ZLAB

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

Original reporting
finance.yahoo.com
Published Oct 23, 2026, 2:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 2:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ZLABBullishMed
01

Why it matters

The disclosed response rates and progression‑free survival are markedly higher than historical chemo‑immunotherapy benchmarks, suggesting a competitive advantage.

02

Market read

Early positive data for Zoci could catalyze Zai Lab's share price and influence the broader oncology biotech sector.

03

What to watch

The upcoming Phase III design and partnership with Boehringer Ingelheim/Amgen may affect valuation more than the early efficacy numbers.

Relevance 8/10Novelty 8/10Timing: today

Background

Zai Lab (NASDAQ:ZLAB) is a China‑focused biopharma developing oncology assets. Zoci is an antibody‑drug conjugate targeting small‑cell lung cancer.

Company-level read

Ticker impact

$ZLABBullishHigh confidence
Context

Zai Lab disclosed early Phase II data for its lung cancer candidate Zoci, showing an 82% response rate and strong progression‑free survival signals.

Expected impact

likely upward pressure as market prices in the strong efficacy data, tempered by noted toxicity concerns.

Evidence & confidence

Efficacy numbers are materially better than historical benchmarks; early data often drive biotech share rallies.

Market effects

Sector

Strengthens the oncology biotech narrative and may lift peer small‑cap cancer therapeutics.

Regional

U.S. biotech sector could see modest gains; Asian investors with exposure to Zai Lab may react similarly.

Global

Adds to the pipeline momentum for biotech firms developing antibody‑drug conjugates globally.

Counterpoint

What could challenge this read

Toxicity signals in the triplet arm could raise safety concerns, potentially limiting upside until later‑stage data.

Key entities

  • company
    Zai Lab Ltd.

    Biopharma developing Zoci.

  • partner
    Boehringer Ingelheim

    Potential collaborator on T‑cell engager combos.

  • partner
    Amgen

    Potential collaborator on T‑cell engager combos.

Read at source← All news

StoryZai Lab raises $250 million in PIPE and reports 81.8% response rate in Phase 1b ES‑SCLC trial

Also covered by

4 outlets

Related articles

OCT 23
$ZLABHighAI 9/10

Why is Zai Lab stock surging today?

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

investing.com2 min
OCT 23
$ZLABMedAI 8/10

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab (ZLAB) reported positive Phase 1b trial results for zocilurtatug pelitecan (zoci) plus atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). The combination achieved an 81.8% response rate and 81.9% 6-month progression-free survival rate. The therapy was well-tolerated, with Grade >3 adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

thailand-business-news.com3 min
OCT 23
$ZLABMedAI 9/10

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

finanznachrichten.de3 min
OCT 23
$ZLABHighAI 9/10

Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.

investing.com2 min